GSK reported that the trial of Jemperli plus chemotherapy in NSCLC patients met the primary endpoint of an objective response rate. Credit: GSK plc.

GSK has reported positive headline data from the Phase II PERLA clinical trial of Jemperli (dostarlimab) plus chemotherapy in first-line, metastatic, non-squamous non-small cell lung cancer (NSCLC) patients.

The randomised, international, double-blind trial assessed the safety and efficacy of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy in 243 subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Objective response rate (ORR) as evaluated by a blinded independent central review per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 was the primary endpoint of the trial. 

Investigator-evaluated progression-free survival (PFS) per RECIST v1.1, safety, and overall survival comprised the trial’s secondary endpoints.

According to the findings, the trial met the primary endpoint of ORR.

Dostarlimab’s safety and tolerability profile in the trial was found to be in line with prior studies that assessed similar regimens. 

Anaemia, nausea, asthenia, constipation, and neutropenia, among others, were reported to be the most prevalent treatment-emergent adverse reactions in the trial.

A programmed death receptor-1 (PD-1)-blocking antibody, Jemperli attaches to the PD-1 receptor and hinders its interaction with PD-L1 and PD-L2, which are the PD-1 ligands. 

Apart from PERLA, the company is also progressing both arms of the COSTAR Lung trial into Phase III. 

The move comes after the Independent Data Monitoring Committee recommended advancing the trial as it met its protocol-based expansion criteria. 

The Phase III COSTAR Lung trial is assessing cobolimab plus dostarlimab and docetaxel versus dostarlimab, plus docetaxel versus docetaxel alone in advanced NSCLC patients.

GSK Oncology Development global head, senior vice-president Hesham Abdullah said: “These trials support the ambition for dostarlimab to become the backbone of our ongoing immuno-oncology-based research and development programme when used alone and in combination with standard of care and future novel cancer therapies, particularly in patients with currently limited treatment options.”

In September this year, the company reported data from the Phase III PRIMA trial where Zejula (niraparib) offered a lasting PFS benefit in ovarian cancer patients.